Home Blog Page 131

Throtle and StackAdapt Collaboration Accelerates Healthcare Audience Targeting Through Advanced Onboarding and Activation Solutions

0
Throtle and StackAdapt Collaboration Accelerates Healthcare Audience Targeting Through Advanced Onboarding and Activation Solutions

Throtle, healthcare’s only dedicated identity resolution provider, and StackAdapt, a leader in multi-channel programmatic advertising, today announced StackAdapt will be leveraging Throtle’s onboarding and activation solutions to significantly enhance healthcare audience targeting capabilities for their clients. This collaboration aims to provide healthcare marketers with unparalleled accuracy and efficiency in reaching their desired audiences through the StackAdapt platform. 

The healthcare industry faces unique challenges in digital marketing, particularly when it comes to accurately targeting and engaging with specific audiences while adhering to privacy regulations. Recognizing this, StackAdapt has chosen Throtle's expertise in precision data management and activation to ensure healthcare messages reach the right individuals with relevant and timely content. 

Throtle is known for its transformative ability to enhance, match and activate healthcare data from online and offline sources, maintaining the highest standards of privacy. This will enable StackAdapt’s clients to benefit from improved match rates, reduced data loss, and enhanced campaign performance, ensuring that their marketing efforts are both effective and compliant with industry regulations. 

Michael Shang, SVP of Advertising Technologies, discussed the benefits of working with Throtle, stating, “Our collaboration represents a significant first step forward in our commitment to delivering cutting-edge solutions to healthcare marketers. By integrating Throtle’s advanced onboarding and activation technologies, we are not only enhancing our platform's capabilities but also ensuring that our clients can engage healthcare audiences more effectively and responsibly than ever before.” 

Paul Chachko, CEO of Throtle, expressed his enthusiasm about working with StackAdapt, adding, “StackAdapt can now offer a comprehensive suite of tools that empower healthcare marketers to navigate the complexities of audience targeting with ease and confidence. Our combined strengths will help healthcare organizations achieve their marketing objectives with greater precision and success, all while prioritizing patient privacy and data security.” 

For more information about Throtle and how it can benefit your healthcare marketing strategy, please visit throtle.io. 

Contact Information:
Maggie Jordan
CSO
[email protected]


Original Source: Throtle and StackAdapt Collaboration Accelerates Healthcare Audience Targeting Through Advanced Onboarding and Activation Solutions

KidsEmail.org Acquired by Internet Safety Expert JT Smith in Strategic Move to Enhance Child Digital Safety

0
KidsEmail.org Acquired by Internet Safety Expert JT Smith in Strategic Move to Enhance Child Digital Safety

Jacob Andersen, the founder of KidsEmail.org, a leading child safety platform, has successfully sold the company to internet safety veteran JT Smith in a deal that underscores the market value of safe digital environments for children. The transaction amount remains confidential, but with over 130,000 parent accounts and a monthly subscription of $4.95, the sale represents a significant investment in the future of online child protection.

Since its inception in 2009, KidsEmail.org has been at the forefront of the internet safety industry, offering robust tools for parents to monitor and control their children's online communication. This ensures a safe, constructive internet experience tailored for young users.

JT Smith, the new owner, brings extensive expertise in internet security, focusing on safe search and secure online experiences. This acquisition is poised to further solidify KidsEmail.org's position as a leader in the child internet safety sector.

Jacob Andersen commented on the sale, saying, "Transferring KidsEmail.org to JT Smith is a significant step forward in ensuring the continued success and expansion of the safe communication services we provide. The value of this transaction reflects the high demand and necessity for dedicated child safety solutions online."

JT Smith also shared his enthusiasm about the acquisition: "Purchasing KidsEmail.org represents a strategic enhancement of our capabilities to safeguard young internet users. With the established user base and revenue from subscriptions, we are excited to innovate and expand upon the strong foundation Jacob has built."

For further information, please contact:

Jacob Andersen

[email protected]

Contact Information:
Jacob Andersen
Founder
[email protected]


Original Source: KidsEmail.org Acquired by Internet Safety Expert JT Smith in Strategic Move to Enhance Child Digital Safety

Avenger co-stars blown away by Renner’s resilience

0
Avenger co-stars blown away by Renner’s resilience

Robert Downey Jr. and Chris Hemsworth had nothing but positives for Avenger Jeremy Renner after reuniting at Chris Evans’ wedding.

There are a few unwritten rules for weddings. One, don’t wear white unless you’re the bride. Two, don’t make a speech unless you are specifically told to do so. And three, this is not your day. By all accounts, Jeremy Renner followed all of these at the wedding of fellow Avenger Chris Evans, but many of his friends and MCU stars couldn’t help but put a spotlight on the actor, who has made one hell of a recovery following his January 1st, 2023 accident.

Speaking on Jeremy Renner’s recovery and just how far he has come in that time, Avengers co-star Robert Downey Jr. said, “If there’s one characteristic we’d all agree is paramount…it’s resilience. To see Renner embody that literally, and in the context of what was basically a Portuguese American wedding, was mind-blowing. Fully recovered and ready to celebrate. So, yes—miracles happen.” “Perseverance” is the perfect word to describe Jeremy Renner, whose well-documented progress through his recovery has made him an Avengers-level superhero to many.

Evans wed Alba Baptista last September, just over eight months after a snowplow weighing over 14,000 pounds crushed him, a near-death experience which resulted in blunt chest trauma and 30 broken bones. While he would probably never brag about it, RDJ proved to be one of Renner’s most consistent Avengers co-stars in terms of checking in and giving good vibes.

Evans’ wedding was actually the first time another Avenger, Chris Hemsworth, had seen Renner since his accident. “He sent us all a sort of a doped out, hospital, beat-up image and said, ‘All good, guys.’ And then I didn’t hear from him for a while as he was in the thick of it.” Hemsworth added, “There was an astounding sense of gratitude from him around just being alive.”

While a lot is up in the air as far as the future of the Marvel Cinematic Universe goes, fifth and sixth Avengers movies are in development, so we’ll have to see just how/if the likes of Renner, RDJ, Hemsworth, and the rest assemble yet again – although some seem more committed than others

What do you want to see Jeremy Renner tackle in the near future? Let us know by dropping a comment below.

Originally published at https://www.joblo.com/avenger-co-stars-blown-away-by-renner-resilience/

Freyja HealthCare’s VereSee™ Device Receives 510(k) Clearance, the First of Many Products

0
Freyja HealthCare’s VereSee™ Device Receives 510(k) Clearance, the First of Many Products
Freyja Healthcare Brings First-of-Its-Kind 2mm Abdominal-Access Device to Laparoscopic Surgery to Further Innovation in Fast-Growing Women’s Health Market

Freyja Healthcare, an early-stage medical device company focused on developing a robust product portfolio of highly innovative products for women’s health, today announced that its novel VereSee device received 510(k) clearance from the United States Food and Drug Administration (FDA). Clearance from the FDA marks a critical step in enabling Freyja and VereSee — the first and only 2mm, safe abdominal-access video-entry device for laparoscopic surgery — to bring further innovation in the fast-growing women’s health market.  VereSee will reinvigorate a category that has not seen innovation in over three decades.

Founded by Jón Ívar Einarsson, MD, PhD, MPH, and Gaby Moawad, MD, FACOG, Freyja’s mission is to raise the standard of women’s health in both surgical and in-office procedures, enabling physicians to deliver safe and effective care. As the company’s first novel product, the VereSee device features a proprietary design engineered to be simple for the surgeon, safe for the patient, and highly differentiated from the current standard of care. The company now has four products in advanced stages of development, 17 granted patents and 21 pending patents.

“From the beginning, I’ve been impressed with Freyja’s mission to improve gynecologic solutions for women and the providers who take care of them. With this first product, Freyja is bringing  meaningful innovation to a category ready for change,” said Kim Rodriguez, longtime Freyja Executive Chairman and former CEO of Acessa Health. 

There are 4.8 million laparoscopic surgeries performed annually in the United States. Abdominal entry is the most dangerous step of laparoscopic and robotic surgery in women’s health, and in all laparoscopic surgery across all specialty areas. This dangerous step results in one patient death and eight injuries in the U.S. each day[1].

“The standard of care is dangerous and outdated. Initial entry is often done blindly with Veres needles or a 5-12mm optical trocar,” said Jón Ívar Einarsson, MD, co-founder and interim CEO of Freyja. “Damaging the bowel or vasculature because of blind entry can cause significant harm, even death, if undetected.” 

As a part of the FDA clearance process, Freyja performed extensive testing and documentation of the safety and efficacy of the product, validating the company’s confidence in the design of its VereSee product. 

“FDA clearance has been a long process for us, and we know that this is one of the largest barriers to entry for new products in this category,” said Gaby Moawad, MD, co-founder and Board Director of Freyja. “However, we understand the importance of these devices being held to the highest standards of safety and quality. We are proud of the work our team has done to reach this milestone for Freyja.”

Freyja will soon begin initial commercialization of the VereSee device, with broad availability expected in the second half of 2024.

About Freyja Healthcare 

Freyja Healthcare was founded in 2017, has four products in advanced stages of development, 17 granted patents and 21 pending patents, and is engineering a robust product portfolio focused on safe and effective surgical and in-office solutions for women. Founded by two well-respected, minimally invasive gynecologic surgeons, Jón Ívar Einarsson, MD, PhD, MPH, Past-President of AAGL, founder of the Division of Minimally Invasive Gynecologic Surgery (MIGS) at Brigham and Women’s Hospital (BWH) and a Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School, and Gaby Moawad, MD, FACOG, Associate Professor of Obstetrics and Gynecology at The George Washington University School of Medicine and Health Sciences (GWSMHS). Drs. Einarsson and Moawad are inventing and building the products they wish they had early in their careers and elevating the standards for products used in women’s health surgical and in-office care. Freyja has raised almost $8 million in seed funding from private and professional high net-worth investors. Learn more at Freyja Healthcare.

[1] Clark NV, Einarsson JI. Laparoscopic entry techniques. In: Minimally invasive surgery in gynecologic practice. De Gruyter 2020.

Contact Information:
Jerry Brecher
[email protected]


Original Source: Freyja HealthCare's VereSee™ Device Receives 510(k) Clearance, the First of Many Products

Yunu Delivers a New Imaging Workflow Paradigm for Investigator-Initiated Trials

0
Yunu Delivers a New Imaging Workflow Paradigm for Investigator-Initiated Trials
Investigators rapidly activate sites, expand trial reach, and achieve real-time data oversight with a complete and affordable cloud-based research imaging platform.

Yunu, creator of a first-of-kind clinical trial imaging workflow, reading, and data management platform, is extending the reach of investigator-initiated trials (IITs) into broader and more diverse communities while harmonizing trial data on its unified cloud-based platform. By leveraging the Yunu ecosystem, Principal Investigators (PIs) are lowering costs, accelerating trial timelines, and improving the accuracy of cross-site IIT research.

Effective collaboration and data management is essential for investigator-initiated trials that need to bridge the gaps associated with reaching patients beyond their primary institution while managing tight budget constraints. Traditionally, multi-site IITs have been fraught with logistical challenges, communication barriers, quality issues leading to assessment errors and protocol violations, and administrative complexities as PIs must often rely on disparate systems and paper-based approaches to manage the tracking of study scheduling, image measurement, patient response, billing, and data storage. Furthermore, fragmented and multi-channel communication has led to trial delays, inefficiencies, and non-compliance. Recognizing these challenges, Yunu empowers PIs to collaborate and coordinate their research endeavors seamlessly by leveraging the innovative platform already in place across over 20% of NCI-designated Comprehensive Cancer Centers.

Principal Investigators and their study staff can now rapidly stand-up trials, add new trial sites, securely manage multi-site data, connect to qualified readers in the Yunuverse, and gain real-time visibility through a single, comprehensive trial dashboard. These collective insights accelerate decision-making and help investigators understand the early signals affecting trial outcomes in real-time. With user-friendly tools for site data de-identification and upload, secure permission-based access rights, and streamlined trial imaging assessment workflow, trial setup and coordination can be centralized while site participation tasks remain harmonized.

"We are ushering in a new era of connected clinical trial workflow to revolutionize the way research is conducted and accelerate the translation of scientific discoveries into real-world impact more quickly," said Gordon Harris, Chief Science Officer and Co-Founder of Yunu. "Our efficient technology-driven approach provides both affordability and extensibility. Trials are reaching patients where they live; sites are scaling their capacity because of the efficiency gains their study staff experience, and PIs are quickly adopting and promoting this new way of working across all sites and stakeholders in real-time.”

About Yunu

Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform daily, Yunu is delivering a new standard for clinical trial imaging workflow.

Learn more at https://www.yunu.io | Inquiries: [email protected]

Contact Information:
Lindsay Fleming
Chief Marketing Officer
[email protected]


Original Source: Yunu Delivers a New Imaging Workflow Paradigm for Investigator-Initiated Trials

Clear Cannabis, Inc. Expands ‘The Clear’ Brand in New Jersey With Kushi Labs

0
Clear Cannabis, Inc. Expands ‘The Clear’ Brand in New Jersey With Kushi Labs
Announcement Coincides with Major Marijuana Reclassification Announcements from The White House Administration


Kushi Labs, Inc. Logo

Kushi Labs, Inc. Logo

In response to growing consumer demand, Clear Cannabis, Inc. (CCI), a leader in cannabis innovation and quality since 2013, is thrilled to announce the expansion of its popular brand, The CLEARTM to New Jersey through a strategic partnership with Kushi Labs. This collaboration marks a significant milestone as the company introduces its top-tier cannabis products to The Garden State. This marks the 12th state for The Clear and its market expansion. 

Under this agreement, CCI will license its IP formulas, processes, and operational knowledge to Kushi Labs. 

"The CLEAR has consistently set the benchmark for excellence and innovation in the cannabis market," said Richard M. Batenburg, Jr., CEO of Clear Cannabis, Inc. "Our decision to bring The CLEAR to New Jersey with Kushi Labs is a testament to our commitment to meet consumer demand and deliver unparalleled cannabis experiences."

The CLEAR's products are celebrated for their unparalleled purity, potency, and palate-pleasing flavors, setting the industry standard for cannabis product excellence. 

This expansion into New Jersey is driven by a strong market demand and a commitment to making these superior products more accessible to discerning consumers in more states. 

Kushi Labs, known in the New Jersey cannabis sector for its exceptional manufacturing processes, will serve as the licensed partner, ensuring that the same high-quality standards known across the U.S. are upheld. The CLEAR’s entry into New Jersey is anticipated to set new benchmarks in the market for product quality and consumer satisfaction.

"Our partnership with Clear Cannabis, Inc. represents a pivotal development in our mission to offer the best cannabis products to New Jersey residents," stated Ajay Patel, CEO of Kushi Labs. "The CLEAR’s reputation for quality and trust makes them the ideal partner for us as we look to elevate the cannabis experience in our state."

This expansion into New Jersey coincides with the Biden administration's recent announcement to reclassify marijuana as a class-3 drug, easing restrictions on its use and research.

“The reclassification of marijuana by the White House is a significant step towards greater acceptance and accessibility of cannabis products, and The CLEAR is proud to be at the forefront of this movement,” said Batenburg.

About The Clear Cannabis, Inc.:

Since its inception in 2013, The CLEAR (part of Clear Cannabis, Inc.) has been at the innovation forefront of the cannabis industry, offering a diverse range of products from vapes to edibles, pre-rolled joints and more. Known for its exceptional flavors and consistent quality, The CLEAR has become one of the most trusted and awarded cannabis brands in the United States. 

From Mild to Wild and Everything Between, The CLEAR has something for everyone, catering to a wide array of lifestyles and preferences, ensuring a premium experience to be enjoyed by all.

For additional information about Clear Cannabis, Inc. and The CLEAR, please visit https://clearcannabisinc.com/.

About Kushi Labs: 

Founded in 2021, Kushi Labs is a leading Licensed Cannabis Manufacturing facility in New Jersey. Dedicated to becoming the primary supplier for cultivators and dispensaries statewide, the company emphasizes innovation and excellence. By integrating advanced technology, Kushi Labs sets high standards in cannabis manufacturing quality and efficiency. Supported by a diverse team of engineers, scientists, businessmen, and connoisseurs, all united by their passion, Kushi Labs commits to delivering outstanding products and services as an industry leader. 

Contact Information:
Brett Schklar
CMO
[email protected]
3038832449
Related Images
Kushi Labs, Inc. Logo
Kushi Labs, Inc. Logo

Kushi Labs, Inc. Logo

The CLEAR Logo
The CLEAR Logo

The CLEAR Logo



Original Source: Clear Cannabis, Inc. Expands 'The Clear' Brand in New Jersey With Kushi Labs

Chris Pine is “stunned” that Wonder Woman 3 isn’t happening

0
Chris Pine is “stunned” that Wonder Woman 3 isn’t happening

Chris Pine admits that he’s “stunned” that Wonder Woman 3 isn’t happening: “I don’t know what the reasoning was behind that.”

As we know, Wonder Woman 3 is no longer moving forward now that James Gunn and Peter Safran have taken over DC Studios, but it’s a choice Chris Pine doesn’t understand.

Chris Pine. who played Steve Trevor in Wonder Woman and Wonder Woman 1984, told Business Insider that he was “stunned” when he learned Wonder Woman 3 had been axed. “I’m stunned that they said no to a billion-dollar franchise and decided to pivot elsewhere,” Pine said “I don’t know what the reasoning was behind that; it’s above my pay grade, but Wonder Woman is an incredible character; Patty is such a thoughtful director.

The actor had no expectations that he would have been involved in the third movie. “Me. No. Homie is dead. Steve is gonzo,” he said. “It would be ridiculous to try to bring me back.” Trevor was killed off in the first Wonder Woman movie but was brought back for Wonder Woman 1984 through a little comic-book magic. As Pine said, it would have been a little ridiculous if they brought him back yet again.

As much as Pine loves the Wonder Woman franchise nowadays, he initially hesitated to sign on. “I had no interest in playing the boyfriend, and it sounded like second fiddle,” Pine said. “Then, in talking to Patty, the way she described it was, ‘Forget the superhero of it all, this is a romance, this is ‘Casablanca,’ that’s the movie I want to make.’ I was like, oh, now that is very cool because when have you seen a superhero film that was a love story, ultimately? That had nothing to do with blowing shit up.

Wonder Woman director Patty Jenkins has said that she doesn’t believe DC Studios is “interested in doing any ‘Wonder Woman’ for the time being,” but she doesn’t hold any ill will. “It’s not an easy task, with what’s going on with DC. James Gunn and Peter Safran have to follow their own heart into their own plans,” Jenkins said. “I don’t know what they are planning on doing or why, so I have sympathy for what a big job it is and they have to follow their heart and do what they’ve got planned.“ At the moment, the only Wonder Woman-related project in development for the new DC Universe is the Paradise Lost prequel series for Max.

Chris Pine will next be seen in Poolman, which he also co-wrote and directed. After catching the flick at the Toronto International Film Festival last year, our own Chris Bumbray said it was one of the worst movies he’s ever reviewed. Yikes. You’ll be able to find out for yourself when Poolman is released on May 10th.

Originally published at https://www.joblo.com/chris-pine-wonder-woman-3/

The Strangers Trilogy: Renny Harlin is planning a 4.5 hour mega-cut

0
The Strangers Trilogy: Renny Harlin is planning a 4.5 hour mega-cut

The Strangers marks Renny Harlin’s return to the horror genre, and his three films are being planned as an odyssey.

Like many of you, I was scratching my head when I learned that director Renny Harlin would be making not one, not two, but three movies based on the horror cult classic The Strangers. While a pretty slick horror flick, the original spawned a modest follow-up that didn’t get a ton of buzz. When it came out, I figured it was a series that had run its course. It seems this is not so, with Lionsgate releasing a widely ambitious trilogy of horror films this year (it’s like the horror version of Kevin Costner’s Horizon). 

Notably, it marks the return of director Renny Harlin to the horror genre. Now mostly known for his action films, such as the classics Die Hard 2, Cliffhanger, The Long Kiss Goodnight, and many more – horror was where he made his original reputation. Prison, which gave Viggo Mortensen his first leading role, was a cult hit, and A Nightmare on Elm Street 4: The Dream Master was a smash. Since then, he’s dipped his toe back into the genre with movies like Deep Blue Sea and Mindhunters, but usually when they’re a hybrid with another genre.

Not so for The Strangers trilogy, which is straight-up horror. According to a recent report in Variety, Harlin shot all three films in one fifty-two-day shoot, and he’s already planning to cut together a 4.5-hour version of the film (from a 285-page script), which will exist as a kind of horror odyssey. As he told Variety, “I definitely want to have that event and see if people take four and a half hours of dread and fear and terror and despair.”

In the interview, Harlin denies the movie is any kind of remake, with him evoking a lot of admiration for the original Bryan Bertino film, even admitting to being intimidated by its quality. “Simply doing a sequel or remake didn’t appeal to me, but this was such an opportunity to have four and a half hours of a case study of victims of a violent crime and the perpetrators and what makes them tick and how it affects a person who goes through this.”

Indeed, the producer Courtney Solomon admits its the hook of the original movie that’s proved to be irresistible: “It’s the primal nature of the original concept, these three random people and unexplained, random acts of violence, which is just so terrifying and real. I don’t know if you can improve upon that, so why don’t we take that basic premise as a starting point and modify it for a bigger story that becomes proper, character-driven horror.  

For a whole lot more on The Strangers: Chapter 1, which opens May 17th, stay tuned to JoBlo as our own Tyler Nichols is attending the premiere in Los Angeles this week. For more on Harlin’s take on The Strangers, check out our exclusive interview with him HERE.

Originally published at https://www.joblo.com/the-strangers-trilogy-renny-harlin-is-planning-a-4-5-hour-mega-cut/

What’s Hot for Mother’s Day, Father’s Day, and Summer Barbecues

0
What’s Hot for Mother’s Day, Father’s Day, and Summer Barbecues
The 'Ove' Glove is the perfect present for Gifting and Grilling Season


The 'Ove Glove'

The ?Ove? Glove is the Hottest Gift for Gifting and Grilling Season

Joseph Enterprises, Inc. announces The 'Ove' Glove as the perfect present for the upcoming gifting and grilling season for Mom, Dad and barbecue enthusiasts. The ‘Ove’ Glove is crafted from the same high-performance material trusted by firefighters, ensuring protection up to 540 degrees.

With over 20 million sold and endorsed by both Consumer Reports and Bon Appetit Magazine, The ‘Ove’ Glove has been hailed as the pinnacle of heat protection for 20 years and is now also available as a BBQ Glove.

Get your hands on the The ‘Ove’ Glove Hot Surface Handler Oven Mitt for a thoughtful Mother’s Day or Father’s Day gift, and make sure that all the barbecue lovers in your life have the The ‘Ove’ Glove BBQ Glove in their grilling tool set.

Whether in the kitchen or by the grill, with its three layers of flame-retardant material, silicon grips, and five-finger flexibility, The ‘Ove’ Glove allows for superior control while handling hot plates and grilling essentials without slippage.

The ‘Ove’ Glove is available at Amazon, ACE, Wegmans, Do It Best, True Value, and Walmart.com and in Canada at Canadian Tire, Home Hardware, London Drug Stores, and other fine stores. For more information on The ‘Ove’ Glove, go to www.oveglove.com.

Ensuring that your heat and flame hand protection gift is the original and only The ‘Ove’ Glove will mean unbeatable performance and peace of mind.

About The ‘Ove’ Glove

Joseph Enterprises, Inc. (JEI) is the home of the original ‘Ove’ Glove. JEI is an integrated consumer product company which designs, markets, and distributes novelty, home, and garden products. JEI rose to success with its two most popular products, the Chia Pet and The Clapper, which are recognized as consumer icons. 

Contact Information:
Jason Blake
[email protected]


Original Source: What's Hot for Mother’s Day, Father’s Day, and Summer Barbecues

Keanu Reeves & Sandra Bullock want to reunite for Speed 3: “We’d freakin’ knock it out of the park”

0
Keanu Reeves & Sandra Bullock want to reunite for Speed 3: “We’d freakin’ knock it out of the park”

Keanu Reeves and Sandra Bullock say that they’re game to reunite for Speed 3: “We’d freakin’ knock it out of the park!”

It’s been thirty years since Keanu Reeves and Sandra Bullock starred alongside one another in Jan de Bont’s classic action thriller Speed, but the pair are game to reunite for Speed 3.

During a joint interview on the 50 MPH podcast, Reeves and Bullock expressed a willingness to return for Speed 3. “I mean, you know — we’d freakin’ knock it out of the park,” Reeves said. Given the success of the first movie, the studio was keen to get a sequel off the ground, but only Bullock returned for Speed 2: Cruise Control, which was a notorious bomb in just about every respect.

Will Speed 3 actually happen? Who knows, but even if it doesn’t, the two actors are aware that they share a special chemistry and would love to work together again. “There’s no formula. It just is,” Bullock said. “Before I die, before I leave this planet, I do think that Keanu and I need to do something in front of the camera. Are we, you know, in wheelchairs or with walkers? Maybe. Are we on little scooters at Disneyland?” Reeves added, “It does feel like there is a siren call to it, like there’s something that wasn’t done. I would love to work with you again before our eyes close.

Bullock has previously admitted that she was still embarrassed by Speed 2. “I have one [that] no one came around to and I’m still embarrassed I was in. It’s called Speed 2,” Bullock said. “I’ve been very vocal about it. Makes no sense. Slow boat. Slowly going towards an island.” Reeves was originally supposed to reprise his role for the sequel but wound up backing out due to the script. “At the time, I didn’t respond to the script,” Reeves said in 2021. “I really wanted to work with Sandra Bullock, I loved playing Jack Traven, and I loved ‘Speed,’ but an ocean liner? I had nothing against the artists involved, but at that time I had the feeling it just wasn’t right.” Jason Patric stepped in to replace Reeves as the male lead.

Would you like to see Keanu Reeves and Sandra Bullock reunite for Speed 3?

Originally published at https://www.joblo.com/speed-3-keanu-reeves-sandra-bullock-reunite/